Tags |
|
|
Links |
|
|
Wiki Articles - Keep Your Powder Dry In A Market Like This
Do you remember the “frenzy” or “froth” moves that were among the wildest aspects of the late-1990s bull
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
run?
In those days it was common to see gains of 20 and 30 points or more in one session. A stock migh
In those days it was common to see gains of 20 and 30 points or more in one session. A stock migh
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
t open at 120, promptly run to 150, settle back to 130, and then sprint to 150 or higher at the close.
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
The true frenzy plays popped at the open on a bit of news or rumor. The excitement spread, pushing the s
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
tock ever higher. Suddenly, the entire market realized that maybe the news wasn’t all that great and may
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
be shares that were selling at $20 yesterday really weren’t worth $50 today. Then the stock often sold o
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
ff hard, pounded by short sellers back down to $20 or lower and the poor souls who bought at $50 were le
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
ft holding the bag.
But for serious day traders with the proper tools and nerves of steel, it was heave
But for serious day traders with the proper tools and nerves of steel, it was heave
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
n.
Today you don’t see those point gains because the price of most stocks is much, much lower. But gain
Today you don’t see those point gains because the price of most stocks is much, much lower. But gain
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
s of 20-30% in one day do appear from time to time.
We’re all human and say to ourselves, “Wow, I wish
We’re all human and say to ourselves, “Wow, I wish
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
I had been in that thing!” when XYZ stock pops from nine to 12 at the open. But you shouldn’t be too eag
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
er to buy into a rocket unless you have the proper day trading tools.
Why? Because the news or hype tha
Why? Because the news or hype tha
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
t drove that stock at the opening bell could dissipate at the moment you place your order. All too often
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
, XYZ will jump from nine to 12 and then head back to nine or even into negative territory as the trader
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
s who got in early cash in their profits. You’ll probably be forced out of your position at a significan
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
t loss as the pain becomes too great. If you hang onto the shares, you could be stuck with a loser for a
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
long, long time.
So if you sense a frenzy building, hop on while it is still in the scope of reality a
So if you sense a frenzy building, hop on while it is still in the scope of reality a
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
nd take the ride up. But once it’s over, it’s over. Get out and walk away. If you missed the initial bui
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
ld-up and the 9-buck stock is at $12, the prudent thing is to stay away. Sure, it could go to $20, but i
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
t’s more likely to go back to $9.
Keep your powder dry. There will be other frothy plays on other days.
Keep your powder dry. There will be other frothy plays on other days.
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.wiki-articles.org.ua/article/104270/wiki-articles-Keep-Your-Powder-Dry-In-A-Market-Like-This.html">Keep Your Powder Dry In A Market Like This</a>
BB link (for phorums):
[url=http://www.wiki-articles.org.ua/article/104270/wiki-articles-Keep-Your-Powder-Dry-In-A-Market-Like-This.html]Keep Your Powder Dry In A Market Like This[/url]
Related Articles:
Angel Investors – How to Interest Them in Your Business
Bookmark it:
|